A recent phase I study reported that 2 out of 15 HNSCC patients (13 %) treated with combination of NOTCH inhibitor MK-0752 and mTOR inhibitor ridaforolimus achieved partial response [74]. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.